Compare Abbott Laboratories (ABT) vs RLX Technology Inc (RLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs RLX Technology Inc — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while RLX Technology Inc trades at $1.96 (market cap $2.32B). The key difference: Abbott Laboratories is far larger — about 72× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.26%). Which is the better fit depends on your goals.
| ABT | RLX | |
|---|---|---|
Market Cap | $166.94B | $2.32B |
Sector | Health | Technology |
52-Week High | $136.62 | $2.73 |
52-Week Low | $82.57 | $1.79 |
Enterprise Value | $193.69B | $955.96M |
Dividend Yield | 2.63% | 5.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
RLX stock trades at $1.96, up 1.55% today, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported strong 2025 results with $3.62B revenue and $922M net income, though recent quarters have missed EPS expectations. Positive news highlights international expansion and a cash-rich, debt-free balance sheet, with JPMorgan increasing its stake significantly in Q3 2025.
Outlook is cautiously optimistic given solid profitability and industry growth potential, but risks include regulatory scrutiny in the vaping sector and consistent earnings misses. The sole analyst coverage recommends Hold, reflecting balanced risk-reward amid high cash flows but uncertain near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
